Literature DB >> 17768124

NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia.

Michela Palmisano, Tiziana Grafone, Emanuela Ottaviani, Nicoletta Testoni, Michele Baccarani, Giovanni Martinelli.   

Abstract

NPM1 mutations have been reported to be the most frequent mutations in acute myeloid leukemia (AML). They are associated with a wide spectrum of morphologic subtypes of AML, normal karyotype and FLT3 mutations. The high frequency of NPM1 mutations might provide a suitable marker for monitoring residual disease of AML.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17768124     DOI： 10.3324/haematol.11202

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  17 in total

1.  Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability.

Authors:  Giovanna Meloni; Marco Mancini; Valentina Gianfelici; Maria Paola Martelli; Robin Foa; Brunangelo Falini
Journal:  Haematologica       Date:  2009-02       Impact factor: 9.941

Review 2.  Minimal residual disease in acute myeloid leukemia--current status and future perspectives.

Authors:  Sabine Kayser; Roland B Walter; Wendy Stock; Richard F Schlenk
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

Review 3.  Life after transplant: are we becoming high maintenance in AML?

Authors:  A M Brunner; A T Fathi; Y B Chen
Journal:  Bone Marrow Transplant       Date:  2016-06-20       Impact factor: 5.483

4.  Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.

Authors:  Preetesh Jain; Hagop Kantarjian; Keyur Patel; Stefan Faderl; Guillermo Garcia-Manero; Ohad Benjamini; Gautam Borthakur; Naveen Pemmaraju; Tapan Kadia; Naval Daver; Aziz Nazha; Raja Luthra; Sherry Pierce; Jorge Cortes; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2013-10-09

5.  Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.

Authors:  Nuria Mencia-Trinchant; Yang Hu; Maria Antonina Alas; Fatima Ali; Bas J Wouters; Sangmin Lee; Ellen K Ritchie; Pinkal Desai; Monica L Guzman; Gail J Roboz; Duane C Hassane
Journal:  J Mol Diagn       Date:  2017-05-16       Impact factor: 5.568

6.  Somatic mutations precede acute myeloid leukemia years before diagnosis.

Authors:  Pinkal Desai; Nuria Mencia-Trinchant; Oleksandr Savenkov; Michael S Simon; Gloria Cheang; Sangmin Lee; Michael Samuel; Ellen K Ritchie; Monica L Guzman; Karla V Ballman; Gail J Roboz; Duane C Hassane
Journal:  Nat Med       Date:  2018-07-09       Impact factor: 53.440

7.  A new DNA-based test for detection of nucleophosmin exon 12 mutations by capillary electrophoresis.

Authors:  Philippe Szankasi; Mohamed Jama; David W Bahler
Journal:  J Mol Diagn       Date:  2008-04-10       Impact factor: 5.568

8.  Nucleophosmin (NPM1) mutations in acute myeloid leukemia: an ongoing (cytoplasmic) tale of dueling mutations and duality of molecular genetic testing methodologies.

Authors:  Gerald Wertheim; Adam Bagg
Journal:  J Mol Diagn       Date:  2008-04-10       Impact factor: 5.568

9.  Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.

Authors:  Tim Pfeiffer; Michael Schleuning; Jiri Mayer; Karl-Heinz Haude; Johanna Tischer; Stefanie Buchholz; Donald Bunjes; Gesine Bug; Ernst Holler; Ralf G Meyer; Hildegard Greinix; Christof Scheid; Maximilian Christopeit; Susanne Schnittger; Jan Braess; Günter Schlimok; Karsten Spiekermann; Arnold Ganser; Hans-Jochem Kolb; Christoph Schmid
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

Review 10.  How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.

Authors:  Marie C Béné; Jaspal S Kaeda
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.